Preclinical large animal models for hematopoietic stem cell transplantation

Current Opinion in Hematology

Volumn 3, Issue 6, 1996, Pages 410-415

  Wagner, John L ^a,b   Storb, Rainer ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CYCLOSPORIN; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR; TACROLIMUS;

ANIMAL MODEL; BONE MARROW TRANSPLANTATION; DRUG EFFICACY; DRUG POTENTIATION; GENE TRANSFER; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; IMMUNOGENETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0029908913     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603060-00003     Document Type: Review

References (59)

1. Abkowitz JL, Catlin SN, Guttorp P: Evidence that hematopoiesis may be a stochastic process in vivo. Nature Med 1996, 2:190-197. Stem cells replicate on average only once every 3 weeks in large animal models such as cats; this could pose a challenge for marrow transplantation and gene therapy.
2. Wagner JL, Burnett RC, DeRose SA, Francisco LV, Storb R, Ostrander EA: Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 1996, in press.
3. Wagner JL, Burnett RC, DeRose SA, Storb R: Molecular analysis and polymorphism of the DLA-DQA gene. Tissue Antigens 1996, in press.
4. Wagner JL, DeRose SA, Burnett RC, Storb R: Brief communication: nucleotide sequence and polymorphism analysis of canine DRA cDNA clones. Tissue Antigens 1995, 45:284-287.
5. Wagner JL, Burnett RC, Storb R: Molecular analysis of the DLA DR region. Tissue Antigens 1996, in press.
6. Wagner JL, Burnett RC, Works JD, Storb R: Molecular analysis of DLA-DRBt polymorphism. Tissue Antigens 1996, in press.
7. Sarmiento UM, DeRose S, Sarmiento JI, Storb R: Allelic variation in the DQ subregion of the canine major histocompatibility complex: 2. DQB. Immunogenetics 1993, 37:148-152.
8. Burnett RC, Geraghty DE: Structure and expression of a divergent canine class I gene. J Immunol 1995, 155:4278-4285.
9. Prilliman K, Lawlor D, Ellexson M, McElwee N, Confer D, Cooper DKC, Kennedy RC, Hildebrand W: Characterization of baboon class I major histocompatibility molecules: implications for baboon-to-human xenotransplantation. Transplantation 1996, 61:989-996.
10. Berenson RJ, Bensinger WI, Kalamasz D, Schuening F, Deeg HJ, Graham T, Storb R: Engraftment of dogs with Ia-positive marrow cells isolated by avidin-biotin immunoadsorption. Blood 1987, 69:1363-1367.
11. + marrow cells engraft lethally irradiated baboons. J Clin Invest 1988, 81:951-955.
12. McSweeney P, Wallace P, Bolles L, Rouleau K, Krizanac-Bengez L, Moore P, Reems J, Beauchamp M, Sale G, Sandmaier BM, Torok-Storb B, Storb R, Nash R: CD34 expression in canine tissues as assessed by a polyclonal antiserum [abstract]. Blood 1995, 86(suppl 1):674a.
13. McSweeney PA, Rouleau KA, Storb R, Bolles L, Wallace PM, Beauchamp M, Krizanac-Bengez L, Moore P, Sale G, Sandmaier B, de Revel T, Appelbaum FR, Nash RA: Canine CD34: cloning of the cDNA and evaluation of an antiserum to recombinant protein. Blood 1996, in press. Characterization of a nonmurine nonprimate CD34 gene that could be useful in expanding the role of the dog model in a study of hematopoiesis.
14. de Revel T, Appelbaum FR, Storb R, Schuening F, Nash R, Deeg J, McNiece I, Andrews R, Graham T: Effects of granulocyte colony stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 1994, 83:3795-3799.
15. Sandmaier BM, Storb R, Santos EB, Krizanac-Bengez L, Lian T, McSweeney PA, Yu C, Schuening FG, Deeg HJ, Graham T: Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood 1996, 87:3508-3513.
16. Andrews RG, Briddell RA, Knitter GH, Rowley SD, Appelbaum FR, McNiece IK: Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 1995, 85:15-20.
17. Abkowitz JL, Persik MT, Shelton GH, Ott RL, Kiklevich JV, Catlin SN, Guttorp P: Behavior of hematopoietic stem cells in a large animal. Proc Natl Acad Sci U S A 1995, 92:2031-2035.
18. Wagner LA, Kiem H-P, McSweeney P, Schuening FG, Storb R, Ostrander EA: Development of a clonality assay for canine hematopoietic stem cells. Blood 1995, 86:3265-3267.
19. Kiem H-P, Darovsky B, von Kalle C, Goehle S, Graham T, Miller AD, Storb R, Schuening FG: Long-term persistence of canine hematopoietic cells genetically marked by retrovirus vectors. Hum Gene Ther 1996, 7:89-96.
20. Barquinero J, Kiem H-P, von Kalle C, Darovsky B, Goehle S, Graham T, Seidel K, Storb R, Schuening FG: Myelosuppressive conditioning improves autologous engraftment of genetically marked hematopoietic repopulating cells in dogs. Blood 1995, 85:1195-1201.
21. Bienzle D, Abrams-Ogg AC, Kruth SA, Ackland-Snow J, Carter RF, Dick JE, Jacobs RM, Kamel-Reid S, Dube ID: Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation. Proc Natl Acad Sci U S A 1994, 91:350-354.
22. van Beusechem VW, Bart-Baumeister JA, Hoogerbrugge PM, Valerio D: Influence of interleukin-3, interleukin-6, and stem cell factor on retroviral transduction of rhesus monkey CD34+ hematopoietic progenitor cells measured in vitro and in vivo. Gene Ther 1995, 2:245-255.
23. Xu LC, Karlsson S, Byrne ER, Kluepfel-Stahl S, Kessler SW, Agricola BA, Sellers S, Kirby M, Dunbar CE, Brady RO, Nienhuis AW, Donahue RE: Long-term in vivo expression of the human glucocerebrosidase gene in nonhuman primates after CD34+ hematopoietic cell transduction with cell-free retroviral vector preparations. Proc Natl Acad Sci U S A 1995, 92:4372-4376.
24. Cobbold S, Metcalfe S: Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens 1994, 43:137-154.
25. Rossbach H-C, Krizanac-Bengez L, Santos EB, Gooley TA, Sandmaier BM: An antibody to CD44 enhances hematopoiesis in long-term marrow cultures. Exp Hematol 1996, 24:221-227.
26. Barsoukov AA, Moore PF, Sandmaier BM: The prospective use of anti-CD3 and anti-TCRαβ monoclonal antibodies for immunosuppression in a canine marrow transplant model [abstract]. Blood 1995, 86(suppl 1):577a.
27. Yu C, Storb R, Mathey B, Deeg HJ, Schuening FG, Graham TC, Seidel K, Burnett R, Wagner JL, Shulman H, Sandmaier BM: DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995, 86:4376-4381.
28. Deeg HJ, Seidel K, Yu C, Nash R, Huss R, Schuening F, Storb R: Delay of radiation-induced decline and recovery of hematopoiesis following treatment with anti-MHC class II antibody. Biol Blood Marrow Transplant 1996, in press.
29. Charley M, Thiele DL, Bennett M, Lipsky PE: Prevention of lethal murine graft versus host disease by treatment of donor cells with L-leucyl-L-leucine methyl ester. J Clin Invest 1986, 78:1415-1420.
30. Raff RF, Severns EM, Storb R, Graham TC, Sale G, Schuening FG, Appelbaum FR: Studies of the use of L-leucyl-L-leucine methyl ester in canine allogeneic marrow transplantation. Transplantation 1993, 55:1244-1249.
31. Kiem H-P, Leisenring W, Raff R, Deeg HJ, Schuening FG, Appelbaum FR, Storb R: Failure of recombinant stem cell factor to enhance engraftment of L-leucyl-leucine methyl ester treated canine marrow after irradiation. Blood 1996, in press.
32. Meiser BM, Kreuzer E, Reiter C, Riethmueller G, Reichart B: CD4, CD8 and CD18 chimeric monoclonal antibodies (chim mAbs) with or without donor bone marrow transplantation for induction of tolerance after heart transplantation (HTx). Proceedings of the Ninth International Congress of Immunology. San Francisco; 1995:650.
33. Kawai T, Cosimi AB, Colvin RB, Powelson J, Eason J, Kozlowski T, Sykes M, Monroy R, Tanaka, Sachs DH: Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995, 59:256-262. Details the effect of cyclosporine allogeneic bone marrow and radiation on renal allograft survival.
34. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen T, Saral R, Santos GW, Colvin OM: Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989, 25:55-61.
35. Ehninger G, Schuler U, Renner U, Ehrsam M, Zeller KP, Blanz J, Storb R, Deeg HJ: Use of a water-soluble busulfan formulation: pharmacokinetic studies in a canine model. Blood 1995, 85:3247-3249.
36. Dix SP, Bucur SZ, Mullins RE, McCulloch W, Thomas GR, Hillyer CD, McClure HM, Strobert EA, Orkin JL, Winton EF: Studies of the pharmacokinetics and toxicity of once daily bolus intravenous busulfan in non-human primates [abstract]. Blood 1995, 86(suppl 1): 225a.
37. Storb R, Raff RF, Deeg HJ, Graham TC, Schuening FG, Shulman H, Bryant E: DLA-identical marrow grafts after low-dose total-body irradiation: addition of viable donor peripheral blood mononuclear cells does not enhance engraftment. Transplantation 1995, 59:1481-1503.
38. Storb R, Deeg HJ: Failure of allogeneic canine marrow grafts after total body irradiation: allogeneic "resistance" vs transfusion induced sensitization. Transplantation 1986, 42:571-580.
39. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Graham TC, Schuening FG, Sale G, Bryant E, Seidel K: Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts. Blood 1994, 83:3384-3389.
40. Nothdurft W, Fliedner TM, Fritz TE, Seed TM: Response of hemopoiesis in dogs to continuous low dose rate total body irradiation. Stem Cells (Dayt) 1995, 13:261-267. Article explores the effect of daily low doses of TBI for up to 1700 days.
41. Wagemaker G: Heterogeneity of radiation sensitivity of hemopoietic stem cell subsets. Stem Cells (Dayt) 1995, 13:257-260.
42. Niemertucker MMB, Sluysmans MMJH, Bakker B, Davelaar J, Zurcher C, Broerse JJ: Long-term consequences of high-dose total-body irradiation on hepatic and renal function in primates. Int J Radiat Biol 1995, 68:83-96.
43. Blazar BR, Widmer MB, Taylor PA, Vallera DA: Promotion of murine marrow alloengraftment and hematopoietic recovery across the major histocompatibility barrier by administration of recombinant human interleukin-1 alpha. Blood 1992, 80:1614-1622.
44. Mathey B, Yu C, Sandmaier BM, Deeg HJ, Graham T, Schuening FG, Nash RA, Storb R: Failure of interleukin-1 and granulocyte-macrophage colony-stimulating factor to enhance allogeneic marrow engraftment and survival in irradiated dogs (letter). Blood 1995, 86:833-834.
45. Nash RA, Schuening FG, Seidel K, Appelbaum FR, Boone T, Deeg HJ, Graham TC, Hackman R, Sullivan-Pepe M, Storb R: Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood 1994, 83:1963-1970.
46. Schuening FG, von Kalle C, Kiem H, Appelbaum FR, Deeg HJ, Pepe M, Gooley T, Graham TC, Hackman R, Storb R: Effect of recombinant canine stem cell factor, a c-kit ligand, on hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. Exp Hematol 1996, in press.
47. Nash RA, Seidel K, Storb R, Slichter S, Schuening FG, Appelbaum FR, Becker AB, Bolles L, Deeg HJ, Graham T, Hackman R, Burstein SA: Effects of rhIL-11 on normal dogs and after sublethal radiation. Exp Hematol 1995, 23:389-396.
48. Laterveer L, Lindley IJD, Hamilton MS, Willemze R, Fibbe WE: Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radio-protective capacity and long-term myelolymphoid repopulating ability. Blood 1995, 85:2269-2275.
49. Nash RA, McSweeney PA, Storb R, Abrams K, Bolles L, Deeg HJ, Feng Z, Hart C, Schuening FG, Slichter S, Grossmann A: Effects of thrombopoietin (rhTPO) in normal dogs after nonlethal total body irradiation (TBI) (200 cGy) [abstract]. Blood 1995, 86(suppl 1):904a.
50. Neelis KJ, Wognum AW, Eaton D, Thomas R, Wagemaker G: Preclinical evaluation of thrombopoietin in rhesus monkeys [abstract]. Blood 1995, 86(suppl 1):256a.
51. Storb R, Deeg HJ, Raff R, Schuening F, Yu C, Sandmaier BM, Graham T: Prevention of graft-versus-host disease: studies in a canine model. In Bone Marrow Transplantation: Foundations for the 21st Century. Edited by Sackstein R, Janssen WE, Elfenbein GJ. New York: Annals of the New York Academy of Sciences; 1995:149-164.
52. Storb R, Rudolph RH, Kolb HJ, Graham TC, Mickelson E, Erickson V, Lerner KG, Kolb H, Thomas ED: Marrow grafts between DLA-matched canine littermates. Transplantation 1973, 15:92-100.
53. Deeg HJ, Storb R, Appelbaum FR, Kennedy MS, Graham TC, Thomas ED: Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. Transplantation 1984, 37:62-65.
54. Wagner JL, Deeg HJ, Seidel K, Anasetti C, Doney K, Sanders J, Sullivan KM, Storb R: Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives: an update of the Seattle experience. Transplantation 1996, 61:54-61.
55. Yu C, Storb R, Deeg HJ, Schuening FG, Nash RA, Graham T: Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease in lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts [abstract]. Blood 1995, 86(suppl 1):577a.
56. Yu C, Storb R, Braude I, Deeg HJ, Schuening FG, Huss R, Graham TC: Corticotropin releasing factor with or without methotrexate for prevention of graft-versus-host disease in DLA-nonidentical unrelated canine marrow grafts. Transplantation 1995, 60:384-404.
57. Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K, Graham TC, Thomas ED: Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of tolerance. Transplantation 1982, 34:30-35.
58. Yu C, Storb R, Deeg HJ, Graham TC, Schuening FG, Huss R, Seidel K, Fitzsimmons WE: Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. Bone Marrow Transplantation 1996, in press.
59. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Fitzsimmons W, Graham TC, Pepe M, Pettinger M, Sale G, van der Jagt R, Schuening FG: FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-nonidentical donors. Transplantation 1993, 56:800-807.